Announcement PDF RNS Number : 8350U Valereum PLC 28 November 2023 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR") 28/11/2023 A close up of a logo Description automatically generated Valereum Plc ("Valereum" or the "Company") Removal of CLN's Update Valereum Plc (AQUIS: VLRM), the Gibraltar technology group, is pleased to announce that the existing Convertible Loan Note under the previous terms of the funding facility announced on 31st January 2022 will be terminated with immediate effect. An agreement has been reached by both parties which will result in no more conversion notes being actioned. James Formolli stated: "This is fantastic news for the company and all its shareholders. Removing the current funding facility is the right thing to do; helping support our strategic ambitions for sustainable growth and shareholder value ahead of any further communications". The directors of the Company accept responsibility for the contents of this announcement. This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. For more information, please visit the Company's website at Valereum.gi Enquiries: Valereum Plc James Formolli, Chairman Tel: +971 4584 6284 AQSE Corporate Adviser First Sentinel Corporate Finance Brian Stockbridge Tel: +44 20 3855 5551 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NEXBVLBLXFLBFBE